Overview: A New Era for Biosimilars The conversation around biosimilars is shifting from incremental improvements to rapid, AI-powered discovery and validation. In this era, Biosim AI—driven by advanced simulations and pharmacometric tools—offers a path to faster timelines, improved predictability, and greater confidence for regulators, manufacturers, and patients. A recent discussion hosted by TD Cowen Insights…